1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

US COVID-19 Relief Law Boosts Pharmaceutical Manufacturing Programs; Is More To Come?

 
• By Bowman Cox

$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.

United States Capitol Building in Washington DC USA
more covid-19 pharma largess

The COVID-19 economic relief/stimulus legislation that the Democrats pushed through the US Congress 10 March builds on investments in domestic pharmaceutical manufacturing infrastructure that the Coronavirus Aid, Relief, and Economic Security (CARES) Act made nearly a year earlier.

Although there is broad bipartisan support for investing in domestic capabilities to manufacture vaccines and treatments for COVID-19 and other...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Compliance

ICH Proposes Global Framework For Managing Leachables In Pharma Products

 
• By Vibha Sharma

The International Council for Harmonisation has developed a holistic approach for the assessment and control of leachable impurities, supporting drug product development, registration and ongoing quality management throughout the product lifecycle.

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By Vibha Ravi

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making the forecasting environment for the pharma industry extremely difficult, the Pink Sheet finds in this infographic analysis.

Manufacturers Can Keep Their Shoes On: FDA PreCheck To Streamline US Facility Applications

 
• By Derrick Gingery

The program would allow early interactions with FDA staff to speed construction and approval of pharmaceutical manufacturing facilities in the US, but will staff be available?